CT-P74 / Celltrion - LARVOL DELTA

The next wave is scheduled to move toward regulators next year. (Korea Biomedical Review) - "Celltrion said it plans to file investigational new drug applications in early 2027 for an additional antibody-drug conjugate, CT-P74, and an FcRn inhibitor, CT-P77, and that it aims to submit a total of 12 investigational new drug applications for new-drug programs by 2028...Celltrion said it is aiming to file an investigational new drug application for CT-G32 in the second half of 2027..."

IND • Immunology • Obesity • Oncology